https://www.selleckchem.com/products/ei1.html
Secondary endpoints compromise overall safety, tumour response, survival and a translational research programme with, among others, the analysis of CC-1 half-life, the induced immune response, as well as the molecular profiling in liquid biopsies. The PSMAxCD3 study was approved by the Ethics Committee of The University Hospital Tübingen (100/2019AMG1) and the Paul-Ehrlich-Institut (3684/02). Clinical trial results will be published in peer-reviewed journals. ClinicalTrials.gov Registry (NCT04104607) and ClinicalTrials.eu Registry (EudraCT2
Like
Comment
Share
